Excess fat mass estimated by waist-circumference-to-height ratio predicts the risk of liver damage better than body mass ...

Excess fat mass estimated by waist circumference-to-height ratio predicts the risk of liver damage better than body mass ...

Physician’s Weekly talked with Andrew M. Moon, MD, and Jaideep Behari, MD, PhD, about the impact of MASH on quality of life, ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief ...

HepaRegeniX GmbH ("HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease ...

Beetroot, a nutritional powerhouse packed with antioxidants, betaine, and nitrates, is emerging as a champion for liver ...

Hepatic steatosis, and the cholestasis associated with this condition, negatively affects experimental and human liver regeneration after hepatectomy or after living donor liver transplantation.

Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting pre-clinical data on DA-1241, a ...